Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) CFO Alan A. Musso sold 29,300 shares of the company’s stock in a transaction on Monday, November 28th. The stock was sold at an average price of $19.51, for a total transaction of $571,643.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) opened at 17.93 on Thursday. The company’s market capitalization is $485.99 million. Bellicum Pharmacueticals Inc. has a 12 month low of $7.24 and a 12 month high of $23.84. The stock has a 50 day moving average of $18.69 and a 200 day moving average of $16.37.

Bellicum Pharmacueticals (NASDAQ:BLCM) last posted its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.63) by $0.03. The firm had revenue of $0.11 million for the quarter, compared to analysts’ expectations of $0.09 million. Bellicum Pharmacueticals had a negative return on equity of 49.65% and a negative net margin of 19,399.12%. Bellicum Pharmacueticals’s revenue was up 90.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.51) earnings per share. Equities analysts anticipate that Bellicum Pharmacueticals Inc. will post ($2.41) EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Bellicum Pharmacueticals (NASDAQ:BLCM)

COPYRIGHT VIOLATION NOTICE: This story was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another website, it was illegally stolen and reposted in violation of U.S. & international copyright law. The original version of this story can be viewed at https://www.thecerbatgem.com/2016/12/01/alan-a-musso-sells-29300-shares-of-bellicum-pharmacueticals-inc-blcm-stock.html.

Several research firms have issued reports on BLCM. Ladenburg Thalmann began coverage on shares of Bellicum Pharmacueticals in a research report on Wednesday. They set a “buy” rating and a $31.00 price target on the stock. Cantor Fitzgerald began coverage on shares of Bellicum Pharmacueticals in a research report on Tuesday, November 1st. They set a “buy” rating and a $32.00 price target on the stock. Zacks Investment Research raised shares of Bellicum Pharmacueticals from a “sell” rating to a “hold” rating in a research report on Monday, October 24th. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $31.00 price target (up from $25.00) on shares of Bellicum Pharmacueticals in a research report on Tuesday, August 9th. Finally, Jefferies Group reaffirmed a “buy” rating on shares of Bellicum Pharmacueticals in a research report on Tuesday, August 23rd. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $26.67.

A number of institutional investors have recently bought and sold shares of BLCM. Baker BROS. Advisors LP purchased a new position in Bellicum Pharmacueticals during the third quarter worth about $96,826,000. FMR LLC increased its position in shares of Bellicum Pharmacueticals by 93.8% in the second quarter. FMR LLC now owns 2,393,544 shares of the biopharmaceutical company’s stock worth $31,020,000 after buying an additional 1,158,544 shares during the period. BlackRock Fund Advisors increased its position in shares of Bellicum Pharmacueticals by 58.3% in the second quarter. BlackRock Fund Advisors now owns 883,201 shares of the biopharmaceutical company’s stock worth $11,446,000 after buying an additional 325,388 shares during the period. First Eagle Investment Management LLC increased its position in shares of Bellicum Pharmacueticals by 45.2% in the second quarter. First Eagle Investment Management LLC now owns 854,055 shares of the biopharmaceutical company’s stock worth $11,069,000 after buying an additional 265,848 shares during the period. Finally, State Street Corp increased its position in shares of Bellicum Pharmacueticals by 152.5% in the second quarter. State Street Corp now owns 283,795 shares of the biopharmaceutical company’s stock worth $3,678,000 after buying an additional 171,400 shares during the period. 68.78% of the stock is currently owned by hedge funds and other institutional investors.

Bellicum Pharmacueticals Company Profile

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

5 Day Chart for NASDAQ:BLCM

Receive News & Stock Ratings for Bellicum Pharmacueticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmacueticals Inc. and related stocks with our FREE daily email newsletter.